How Neurology M&A Has Evolved Over The Last Decade: Upfronts, Multiples And Mechanisms
An analysis of 75 disclosed acquisitions in the neurology sector totaling over $180bn reveals widening deal values, structurally shifting indication preferences, compressing return multiples, and a new dataset linking acquisition stage and price to post-acquisition clinical outcomes.
How Neurology M&A Has Evolved Over The Last Decade: Upfronts, Multiples And Mechanisms
Published on Norstella
Authors: Erik Matson and Oded Ben-Joseph
Abstract:
An analysis of 75 disclosed acquisitions in the neurology sector totaling over $180bn reveals widening deal values, structurally shifting indication preferences, compressing return multiples, and a new dataset linking acquisition stage and price to post-acquisition clinical outcomes.
News
Outcome Capital Named Top Life Sciences Advisory and Strategic Investment Banking Solutions Provider for 2026
Outcome Capital has been named Life Sciences Review’s exclusive recipient of the “Top Life Sciences Advisory and Strategic Investment Banking Solutions 2026” award, recognizing its unique approach to helping life sciences companies move innovations from development to commercialization. The firm combines scientific, clinical, operational, and financial expertise to support emerging and growth-stage companies with fundraising, […]
Read MoreResources
Outcome Capital Life Science Pulse
Outcome Capital Life Science Market Pulse May 2026 Click to view our LifeSciences Pulse Newsletter
DownloadContact Us for More Information
Would you like to learn more about working with Outcome Capital or discuss your specific needs?
© Outcome Capital 2026. Member of Financial Industry Regulatory Authority (FINRA) and the Securities Investment Protection Corporation (SIPC). Check the background of this firm on FINRA’s BrokerCheck.
Outcome Capital and Outcome Life Sciences are affiliates of Outcome Holdings, LLC
Business Continuity Plan | Privacy Policy | Regulation Best Interest
